Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12816056 | 0.87 | — | — | |
| SCHEMBL1567949 | 0.86 | ACACB (0.32) | PROKR1 | |
| SCHEMBL12814831 | 0.85 | ACACB (0.37) | — | |
| SCHEMBL12816668 | 0.82 | — | — | |
| SCHEMBL1118010 | 0.82 | UHRF1 (0.36) | — | |
| SCHEMBL15311827 | 0.81 | MKNK1 (0.32) | LOXL2 | |
| SCHEMBL16012071 | 0.81 | RECQL (0.34) | LOXLOXL2 | |
| SCHEMBL1257059 | 0.81 | NOS3 (0.38) | — | |
| SCHEMBL22954215 | 0.79 | LOX (0.44) | LOXLOXL2ACVR2ATGFBR2SLC13A5 | |
| SCHEMBL16008776 | 0.78 | CHRNA7 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924258-A | Pyridone compound derivative and application thereof | 复旦大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-111205310-B | Heterocyclic fused pyrimidine derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-115772117-A | 2-hydroxysuccinic acid compound and pharmaceutical composition and application thereof | 中国药科大学 | 2023-03-10 | — | — | CN | disclosed |
| EP-3402799-B1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-111285859-B | 2,4, 5-trisubstituted pyrimidine compounds with HIV-1 reverse transcriptase as target, and preparation method and application thereof | 山东大学 | 2021-07-02 | — | — | CN | disclosed |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| CN-111285859-A | 2,4, 5-trisubstituted pyrimidine compounds with HIV-1 reverse transcriptase as target, and preparation method and application thereof | 山东大学 | 2020-06-16 | — | — | CN | disclosed |
| CN-111205310-A | Heterocyclic fused pyrimidine derivative, and pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2020-05-29 | — | — | CN | disclosed |
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3402799-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012089633-A9 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-08-23 | — | — | WO | disclosed |
| US-20120208804-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | VITAE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2012089633-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-07-05 | — | — | WO | disclosed |
| EP-2440537-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | Vitae Pharmaceuticals, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011011123-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | LOX 3146/4885LOXL2 4297/4885ACVR2A 2858/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | LOX 3516/4885LOXL2 3072/4885ACVR2A 2503/4885 |
| US-20120208804-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | HSD11B1, HSD11B2, HSD17B1 | LOX 3314/4885LOXL2 3839/4885ACVR2A 2027/4885 |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | LOX 3146/4885LOXL2 4297/4885ACVR2A 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.